Inhibitory control of angiotensin-converting enzyme by ramipril in migraine
Neurology Asia
;
: 289-291, 2013.
Article
in English
| WPRIM
| ID: wpr-628704
ABSTRACT
Background:
Renin-angiotensin systems (RAS) are involved in the physiology of migraine. Ramipril is an angiotensin-converting enzyme inhibitor. We tested whether ramipril has an effect on migraine.Methods:
The study was designed as a prospective open-labeled trial in a single center. All patients were asked to maintain a headache diary. Ramipril was administered at 5mg/day (2.5mg twice a day) and subjects were checked every 4 weeks up to 12 weeks.Results:
The mean number of headache days was 19.9 ± 11.2 days per month at baseline, and 12.0 ± 11.5 at 12 weeks (p vs. <15 days a month) did not show a difference. Mean blood pressure was not altered.Conclusions:
Ramipril prevented migraine attacks independently from blood pressure. This result supports a link between renin-angiotensin system and migraine pathophysiology (Clinicaltrials.gov identifier NCT01402479).
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
English
Journal:
Neurology Asia
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS